piplartine and Chemical-and-Drug-Induced-Liver-Injury

piplartine has been researched along with Chemical-and-Drug-Induced-Liver-Injury* in 1 studies

Other Studies

1 other study(ies) available for piplartine and Chemical-and-Drug-Induced-Liver-Injury

ArticleYear
Evaluation of Hepatoprotective Effects of Piperlongumine Derivative PL 1-3-Loaded Albumin Nanoparticles on Lipopolysaccharide/d-Galactosamine-Induced Acute Liver Injury in Mice.
    Molecular pharmaceutics, 2022, 12-05, Volume: 19, Issue:12

    In recent years, piperlongumine (PL) having specific cytotoxicity has attracted considerable attention for anticancer activity. Through structural modification, the active derivative PL 1-3 shows potential anti-inflammatory activity and low cytotoxicity, but its water solubility is low. Here, PL 1-3-loaded bovine serum albumin nanoparticles (1-3 NPs) were prepared and characterized, which can improve the dissolution. 1-3 NPs exhibited effective hepatoprotective effects on lipopolysaccharide/d-galactosamine-induced acute liver injury of mice, which was similar to liver injury in clinical settings. 1-3 NPs treatment can inhibit inflammation, oxidative stress, and apoptosis via the downregulation of NF-κB signaling pathways, the activation of Nrf2/HO-1 signaling pathways, and the inhibition of expression of Bax and caspase 3 proteins. The above results demonstrated that PL 1-3-loaded bovine serum albumin nanoparticles possessed potential value in intervention of inflammation-based liver injury.

    Topics: Animals; Chemical and Drug Induced Liver Injury; Galactosamine; Inflammation; Lipopolysaccharides; Liver; Mice; Nanoparticles; NF-E2-Related Factor 2; NF-kappa B; Serum Albumin, Bovine

2022